From: IL32 expression in peripheral blood CD3+ cells from myelodysplastic syndromes patients
Factor | Univariate analysis | Multivariate analysis | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Event free survival | Overall survival | Event free survival | Overall survival | |||||||||
HRa | (95% CI) | p | HRa | (95% CI) | p | HRa | (95% CI) | p | HRa | (95% CI) | p | |
WHO 2008 classification | ||||||||||||
RAEB-1/RAEB-2 vs. RA/RARS/RCMD | 2.73 | 0.92–8.04 | 0.07 | 3.93 | 1.35–11.47 | 0.01 | 8.24 | 2.20–30.84 | 0.003 | 5.58 | 1.75–17.77 | 0.003 |
Gender | ||||||||||||
Male vs. female | 4.74 | 1.52–14.76 | 0.007 | 3.33 | 1.15–9.64 | 0.03 | 9.43 | 2.57–34.48 | 0.02 | 4.17 | 1.35–12.82 | 0.01 |
Age | 1.05 | 1.01–1.09 | 0.02 | 1.05 | 1.01–1.09 | 0.02 | - | - | - | 1.06 | 1.01–1.11 | 0.03 |
IL32 expression | 1.14 | 0.98–1.33 | 0.09 | 1.08 | 0.96–1.22 | 0.23 | 0.49 | 0.25–0.94 | 0.006 | - | - | - |
IL32α expression | 1.08 | 1.01–1.15 | 0.02 | 1.04 | 0.98–1.09 | 0.18 | 3.25 | 1.69–6.25 | 0.02 | - | - | - |
IL32β expression | 1.04 | 0.81–1.32 | 0.77 | 1.03 | 0.85–1.24 | 0.80 | - | - | - | - | - | - |
IL32γ expression | 1.04 | 0.96–1.14 | 0.32 | 1.03 | 0.96–1.11 | 0.42 | - | - | - | - | - | - |
IL32δ expression | 1.04 | 0.99–1.08 | 0.06 | 1.02 | 0.98–1.05 | 0.34 | 0.63 | 0.47–0.85 | 0.02 | - | - | - |